The Response of Hodgkin's Disease to Treatment with Oral Vinblastine Sulfate
Authors: Henry E. Wilson, John Louis
Journal: Annals of Internal Medicine (1967)

Article1 August 1967The Response of Hodgkin's Disease to Treatment with Oral Vinblastine SulfateHENRY E. WILSON, M.D., F.A.C.P., JOHN LOUIS, M.D., F.A.C.P.HENRY E. WILSON, M.D., F.A.C.P.Search for more papers by this author, JOHN LOUIS, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-67-2-303 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptEarly studies by the Midwest Cooperative Chemotherapy Group to determine the therapeutic spectrum for parenteral vinblastine sulfate* indicated that Hodgkin's disease was the most responsive tumor (1).The obvious advantages of an effective oral route of administration and the knowledge that there is significant gastrointestinal absorption of vinblastine sulfate have made it desirable to define the optimal limits of oral dosage. Earlier comparative studies of the oral and parenteral routes of administration suggested that responses could be obtained by the orally administered drug in doses two to three times that of the intravenous dose. However, the wide variation in dosage...References1. WRIGHTHURLEYKORSTMONTOROHNWILLLOUIS TLJDRRWRJJJJ MIDWEST COOPERATIVE CHEMOTHERAPY GROUP: : Vinblastine (vincaleukoblastine) in neoplastic disease. Cancer Res. 23: 169, 1963. Google Scholar2. HODESROHNBONDYARDLEY MERJWHJ: Vincaleukoblastine. III. Clinical trial with the oral preparation. Cancer Chemother. Rep. 14: 129, 1961. MedlineGoogle Scholar3. HODESROHNBONDYARDLEY MERJWHJ: Oral vinblastine. Cancer Chemother. Rep. 12: 190, 1961. MedlineGoogle Scholar4. ARMSTRONGDYKEFOUTS JGRWPJ: Vinblastine sulfate treatment of Hodgkin's disease during a pregnancy. Science 143: 703, 1964. CrossrefMedlineGoogle Scholar5. ARMSTRONGDYKEFOUTSJANSEN JGRWPJCJ: Delivery of a normal infant during vinblastine sulfate therapy for Hodgkin's disease. Ann. Intern. Med. 61: 106, 1964. LinkGoogle Scholar6. BONDROHNYARDLEYHODES WHRJJME: Dose-response comparison on oral and intravenous forms of VLB (vinblastine sulfate) (abstract). Proc. Amer. Ass. Cancer Res. 3: 211, 1961. Google Scholar7. A Cooperative Study: Neoplastic disease, treatment with vinblastine. Arch. Intern. Med. (Chicago) 116: 846, 1966. Google Scholar8. KORSTNIXON DRJC: Oral administration of vinblastine sulfate (NSC-49842) to cancer patients. Cancer Chemother. Rep. 45: 53, 1965. MedlineGoogle Scholar9. MCDONALDLACHER CAMJ: Oral vinblastine sulfate in Hodgkin's disease. Clin. Pharmacol. Ther. 7: 534, 1966. CrossrefMedlineGoogle Scholar10. LOUIS J: Phase I des études coordonnées de la chimiotherapie du cancer aux Etats-Unis. Acta Un. Int. Cancr. 19: 997, 1963. MedlineGoogle Scholar11. HEWLETTBATTLEBISHOPFOWLERSCHWARTZHAGENLOUIS JSJDRCWMSOPSJ: Phase II study of A-8103 (NSC-25154) in acute leukemia in adults. Cancer Chemother. Rep. 42: 25, 1964. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Midwest Cooperative Chemotherapy GroupDrs. Wilson and Louis are the Writing Committee for the Midwest Cooperative Chemotherapy Group. For the list of contributing institutions and investigators, see the note after the summary of this paper.These studies were supported by research grants to the Midwest Cooperative Chemotherapy Group from Abbott Laboratories, Eli Lilly & Co., and Lederle Laboratories.Requests for reprints should be addressed to John Louis, M.D., Loyola University School of Medicine, 706 S. Wolcott St., Chicago, Ill. 60612.*The vinblastine sulfate (Velban®) used in the present study was prepared and supplied by the Eli Lilly & Co. laboratories, J. Armstrong, M.D., Indianapolis, Ind. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTherapy of Relapsed Hodgkin LymphomaTreatment of Hodgkin's Disease: Results Obtained by Individualized Treatment Using Radiotherapy and CytostaticsMegaloblastic anemia in the course of Vinblastine sulphate (VELBE) therapyVinblastine in the treatment of advanced Hodgkin's disease 1 August 1967Volume 67, Issue 2Page: 303-308KeywordsChemotherapyDrugsHodgkin lymphomaHospitalsOral administrationResearch grantsRoutes of administrationSulfates Issue Published: 1 August 1967 PDF downloadLoading ...